Shareholders of Plus Therapeutics, Inc. (NASDAQ:PSTV) voted on four proposals at the company’s 2026 annual meeting held Wednesday. The information is based on a press release statement and the company’s SEC filing.
At the meeting, shareholders elected Howard Clowes, An van Es-Johansson, M.D., Richard J. Hawkins, Marc H. Hedrick, M.D., Ronald A. Andrews, and Kyle Guse, Esq., MBA, CPA to the board of directors for terms expiring at the 2027 annual meeting. The election results for each director reflected votes in favor ranging from approximately 11.9 million to 12.4 million, with votes withheld ranging from about 1.6 million to 2.2 million. There were 50.8 million broker non-votes on each director.
Shareholders also ratified the appointment of CBIZ CPAs, P.C. as the company’s independent registered public accounting firm for the 2026 fiscal year. The proposal received approximately 60.9 million votes for, 2.3 million against, and 1.7 million abstentions, with no broker non-votes.
In an advisory (non-binding) vote, shareholders approved the compensation of the company’s named executive officers, with 10.4 million votes for, 3.4 million against, and 0.3 million abstentions, and 50.8 million broker non-votes.
Additionally, shareholders approved the sixth amendment and restatement of the company’s 2020 Stock Incentive Plan. The proposal received about 8.0 million votes for, 5.6 million against, 0.4 million abstentions, and 50.8 million broker non-votes.
The company reported that 64.9 million shares were represented at the meeting, constituting a quorum out of 171.6 million shares outstanding as of the record date, March 18, 2026. All share amounts are presented before the company’s 1-for-25 reverse stock split effective April 2, 2026.
The vote results were certified by the inspector of elections.
